168 related articles for article (PubMed ID: 12670534)
1. Therapeutic potential of phosphoinositide 3-kinase inhibitors.
Ward S; Sotsios Y; Dowden J; Bruce I; Finan P
Chem Biol; 2003 Mar; 10(3):207-13. PubMed ID: 12670534
[TBL] [Abstract][Full Text] [Related]
2. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents.
Ward SG; Finan P
Curr Opin Pharmacol; 2003 Aug; 3(4):426-34. PubMed ID: 12901953
[TBL] [Abstract][Full Text] [Related]
3. Isoform selective phosphoinositide 3-kinase gamma and delta inhibitors and their therapeutic potential.
Ghigo A; Hirsch E
Recent Pat Inflamm Allergy Drug Discov; 2008 Jan; 2(1):1-10. PubMed ID: 19075988
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies.
Foster JG; Blunt MD; Carter E; Ward SG
Pharmacol Rev; 2012 Oct; 64(4):1027-54. PubMed ID: 23023033
[TBL] [Abstract][Full Text] [Related]
5. PI3K inhibitors as potential therapeutics for autoimmune disease.
Ball J; Archer S; Ward S
Drug Discov Today; 2014 Aug; 19(8):1195-9. PubMed ID: 24735732
[TBL] [Abstract][Full Text] [Related]
6. Phosphoinositide 3-kinases in health and disease.
Ghigo A; Morello F; Perino A; Hirsch E
Subcell Biochem; 2012; 58():183-213. PubMed ID: 22403077
[TBL] [Abstract][Full Text] [Related]
7. Novel 1,5-naphthyridine PI3Kδ inhibitors, an evaluation of WO2011075628.
Norman P
Expert Opin Ther Pat; 2011 Nov; 21(11):1805-10. PubMed ID: 21939430
[TBL] [Abstract][Full Text] [Related]
8. PI3K inhibitors in inflammation, autoimmunity and cancer.
Stark AK; Sriskantharajah S; Hessel EM; Okkenhaug K
Curr Opin Pharmacol; 2015 Aug; 23():82-91. PubMed ID: 26093105
[TBL] [Abstract][Full Text] [Related]
9. Phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors for the treatment of inflammation and autoimmune disease.
Venable JD; Ameriks MK; Blevitt JM; Thurmond RL; Fung-Leung WP
Recent Pat Inflamm Allergy Drug Discov; 2010 Jan; 4(1):1-15. PubMed ID: 20017720
[TBL] [Abstract][Full Text] [Related]
10. Selective PI3Kδ inhibitors, a review of the patent literature.
Norman P
Expert Opin Ther Pat; 2011 Nov; 21(11):1773-90. PubMed ID: 22017414
[TBL] [Abstract][Full Text] [Related]
11. Targeting phosphoinositide 3-kinase: moving towards therapy.
Marone R; Cmiljanovic V; Giese B; Wymann MP
Biochim Biophys Acta; 2008 Jan; 1784(1):159-85. PubMed ID: 17997386
[TBL] [Abstract][Full Text] [Related]
12. Structural Determinants of Isoform Selectivity in PI3K Inhibitors.
Miller MS; Thompson PE; Gabelli SB
Biomolecules; 2019 Feb; 9(3):. PubMed ID: 30813656
[TBL] [Abstract][Full Text] [Related]
13. PI3K inhibitors in cardiovascular disease.
Eisenreich A; Rauch U
Cardiovasc Ther; 2011 Feb; 29(1):29-36. PubMed ID: 20626398
[TBL] [Abstract][Full Text] [Related]
14. Exploring the potential of PI3K inhibitors for inflammation and cancer.
Crabbe T
Biochem Soc Trans; 2007 Apr; 35(Pt 2):253-6. PubMed ID: 17371252
[TBL] [Abstract][Full Text] [Related]
15. Isoform-Selective PI3K Inhibitors for Various Diseases.
Bheemanaboina RRY
Curr Top Med Chem; 2020; 20(12):1074-1092. PubMed ID: 31903879
[TBL] [Abstract][Full Text] [Related]
16. Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity.
Gong GQ; Kendall JD; Dickson JMJ; Rewcastle GW; Buchanan CM; Denny WA; Shepherd PR; Flanagan JU
Biochem J; 2017 Jun; 474(13):2261-2276. PubMed ID: 28526744
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Highly Isoform Selective Thiazolopiperidine Inhibitors of Phosphoinositide 3-Kinase γ.
Collier PN; Messersmith D; Le Tiran A; Bandarage UK; Boucher C; Come J; Cottrell KM; Damagnez V; Doran JD; Griffith JP; Khare-Pandit S; Krueger EB; Ledeboer MW; Ledford B; Liao Y; Mahajan S; Moody CS; Roday S; Wang T; Xu J; Aronov AM
J Med Chem; 2015 Jul; 58(14):5684-8. PubMed ID: 26121481
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidylinositol 3-kinase isoforms as novel drug targets.
Błajecka K; Borgström A; Arcaro A
Curr Drug Targets; 2011 Jun; 12(7):1056-81. PubMed ID: 21291386
[TBL] [Abstract][Full Text] [Related]
19. Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.
Shuttleworth SJ; Silva FA; Cecil AR; Tomassi CD; Hill TJ; Raynaud FI; Clarke PA; Workman P
Curr Med Chem; 2011; 18(18):2686-714. PubMed ID: 21649578
[TBL] [Abstract][Full Text] [Related]
20. The Role of PI3K Isoforms in Autoimmune Disease.
Ward SG
Curr Top Microbiol Immunol; 2022; 436():337-347. PubMed ID: 36243851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
